(MCRI) Monarch Casino & Resort - Ratings and Ratios
Casino, Hotel, Spa, Restaurant
Dividends
| Dividend Yield | 1.21% |
| Yield on Cost 5y | 2.53% |
| Yield CAGR 5y | -79.66% |
| Payout Consistency | 73.1% |
| Payout Ratio | 21.5% |
| Risk via 10d forecast | |
|---|---|
| Volatility | 23.7% |
| Value at Risk 5%th | 34.9% |
| Relative Tail Risk | -10.43% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.46 |
| Alpha | 4.61 |
| CAGR/Max DD | 0.52 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.619 |
| Beta | 0.674 |
| Beta Downside | 0.747 |
| Drawdowns 3y | |
|---|---|
| Max DD | 23.68% |
| Mean DD | 8.36% |
| Median DD | 8.48% |
Description: MCRI Monarch Casino & Resort November 12, 2025
Monarch Casino & Resort, Inc. (NASDAQ:MCRI) operates two full-service casino-hotel properties: the Atlantis Casino Resort Spa in Reno, Nevada, and the Monarch Casino Resort Spa Black Hawk in Colorado. Both assets combine gaming floors, hotel rooms, food-and-beverage venues, and spa amenities, and the company also holds additional undeveloped land parcels. Incorporated in 1993, Monarch is headquartered in Reno, Nevada.
Key performance indicators that typically drive Monarch’s earnings include same-store gaming revenue growth (historically 3-5% YoY when regional tourism is strong), hotel occupancy rates (averaging 70-75% across both locations), and average daily rate (ADR) trends that track regional consumer spending. The business is sensitive to macro-economic drivers such as discretionary income, employment levels in Nevada and Colorado, and the regulatory environment governing casino licensing and taxation.
For a deeper quantitative dive, you may want to explore the MCRI page on ValueRay to see the latest financial metrics and analyst projections.
Piotroski VR‑10 (Strict, 0-10) 7.0
| Net Income (82.7m TTM) > 0 and > 6% of Revenue (6% = 32.4m TTM) |
| FCFTA 0.17 (>2.0%) and ΔFCFTA 6.56pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue -1.15% (prev -10.03%; Δ 8.88pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.23 (>3.0%) and CFO 164.4m > Net Income 82.7m (YES >=105%, WARN >=100%) |
| Net Debt (-94.1m) to EBITDA (158.0m) ratio: -0.60 <= 3.0 (WARN <= 3.5) |
| Current Ratio 0.96 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (18.7m) change vs 12m ago -0.05% (target <= -2.0% for YES) |
| Gross Margin 52.73% (prev 48.93%; Δ 3.79pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 77.28% (prev 76.86%; Δ 0.42pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 67.34 (EBITDA TTM 158.0m / Interest Expense TTM 1.54m) >= 6 (WARN >= 3) |
Altman Z'' 7.20
| (A) -0.01 = (Total Current Assets 134.0m - Total Current Liabilities 140.2m) / Total Assets 725.4m |
| (B) 0.80 = Retained Earnings (Balance) 580.3m / Total Assets 725.4m |
| (C) 0.15 = EBIT TTM 103.8m / Avg Total Assets 698.3m |
| (D) 3.48 = Book Value of Equity 580.5m / Total Liabilities 167.0m |
| Total Rating: 7.20 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 85.57
| 1. Piotroski 7.0pt |
| 2. FCF Yield 7.38% |
| 3. FCF Margin 22.69% |
| 4. Debt/Equity 0.02 |
| 5. Debt/Ebitda -0.60 |
| 6. ROIC - WACC (= 7.27)% |
| 7. RoE 15.37% |
| 8. Rev. Trend 78.97% |
| 9. EPS Trend 58.32% |
What is the price of MCRI shares?
Over the past week, the price has changed by +2.89%, over one month by +3.36%, over three months by -4.81% and over the past year by +14.28%.
Is MCRI a buy, sell or hold?
- Strong Buy: 1
- Buy: 0
- Hold: 3
- Sell: 0
- Strong Sell: 1
What are the forecasts/targets for the MCRI price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 107.2 | 8.5% |
| Analysts Target Price | 107.2 | 8.5% |
| ValueRay Target Price | 104.2 | 5.4% |
MCRI Fundamental Data Overview December 05, 2025
P/E Trailing = 21.7687
P/E Forward = 15.949
P/S = 3.2497
P/B = 3.1469
P/EG = 1.89
Beta = 1.419
Revenue TTM = 539.6m USD
EBIT TTM = 103.8m USD
EBITDA TTM = 158.0m USD
Long Term Debt = 13.6m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 1.01m USD (from shortTermDebt, last quarter)
Debt = 13.6m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -94.1m USD (from netDebt column, last quarter)
Enterprise Value = 1.66b USD (1.75b + Debt 13.6m - CCE 107.6m)
Interest Coverage Ratio = 67.34 (Ebit TTM 103.8m / Interest Expense TTM 1.54m)
FCF Yield = 7.38% (FCF TTM 122.5m / Enterprise Value 1.66b)
FCF Margin = 22.69% (FCF TTM 122.5m / Revenue TTM 539.6m)
Net Margin = 15.32% (Net Income TTM 82.7m / Revenue TTM 539.6m)
Gross Margin = 52.73% ((Revenue TTM 539.6m - Cost of Revenue TTM 255.1m) / Revenue TTM)
Gross Margin QoQ = 46.37% (prev 57.90%)
Tobins Q-Ratio = 2.29 (Enterprise Value 1.66b / Total Assets 725.4m)
Interest Expense / Debt = 4.24% (Interest Expense 575.0k / Debt 13.6m)
Taxrate = 18.51% (7.17m / 38.7m)
NOPAT = 84.6m (EBIT 103.8m * (1 - 18.51%))
Current Ratio = 0.96 (Total Current Assets 134.0m / Total Current Liabilities 140.2m)
Debt / Equity = 0.02 (Debt 13.6m / totalStockholderEquity, last quarter 558.4m)
Debt / EBITDA = -0.60 (Net Debt -94.1m / EBITDA 158.0m)
Debt / FCF = -0.77 (Net Debt -94.1m / FCF TTM 122.5m)
Total Stockholder Equity = 537.8m (last 4 quarters mean from totalStockholderEquity)
RoA = 11.40% (Net Income 82.7m / Total Assets 725.4m)
RoE = 15.37% (Net Income TTM 82.7m / Total Stockholder Equity 537.8m)
RoCE = 18.83% (EBIT 103.8m / Capital Employed (Equity 537.8m + L.T.Debt 13.6m))
RoIC = 15.74% (NOPAT 84.6m / Invested Capital 537.8m)
WACC = 8.46% (E(1.75b)/V(1.77b) * Re(8.50%) + D(13.6m)/V(1.77b) * Rd(4.24%) * (1-Tc(0.19)))
Discount Rate = 8.50% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -2.22%
[DCF Debug] Terminal Value 79.83% ; FCFE base≈101.2m ; Y1≈123.5m ; Y5≈205.8m
Fair Price DCF = 175.9 (DCF Value 3.21b / Shares Outstanding 18.3m; 5y FCF grow 23.62% → 3.0% )
EPS Correlation: 58.32 | EPS CAGR: 14.75% | SUE: 1.01 | # QB: 2
Revenue Correlation: 78.97 | Revenue CAGR: 6.93% | SUE: -0.71 | # QB: 0
EPS next Quarter (2026-03-31): EPS=1.14 | Chg30d=-0.018 | Revisions Net=+0 | Analysts=2
EPS next Year (2026-12-31): EPS=5.85 | Chg30d=-0.030 | Revisions Net=+0 | Growth EPS=+4.5% | Growth Revenue=+4.0%
Additional Sources for MCRI Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle